News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 120
- Sources here
- 24
- Companies here
- 6
Search results
Stored financial headlines
Active search
120 matching headlines
Ticker or company: JUPMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. CEO Christer Rosén and President Alison Silva to discuss the company's recent acquisition of exclusive U.S. rights to ALA-002, a patented MDMA formulation, valued at up to $100 million. This deal transforms Jupiter into …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech
Jupiter Neurosciences Inc. has secured exclusive U.S. rights to Pharmala Biotech's ALA-002, an MDMA formulation for neuropsychiatric conditions, in a deal valued up to US$100 million. This agreement expands Jupiter's focus from neurodegeneration to also include neuropsychiatric disorders, creating a dual clinical-stage pipeline. The …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M
Jupiter Neurosciences has acquired the U.S. rights to ALA-002, a drug developed by Saneron CCEL Therapeutics for neurological and neuro-ophthalmic disorders, in a deal potentially worth up to $100 million. The agreement includes an upfront payment, milestone payments, and royalties on future sales. This …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter Neurosciences licenses MDMA drug ALA-002
Jupiter Neurosciences has licensed exclusive US rights to PharmAla Biotech Holdings' MDMA drug ALA-002, intended for neuropsychiatric disorders like PTSD and anxiety. The deal includes an upfront payment of $3.3 million and potential milestones up to $20 million upon FDA approval. This agreement signifies …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002
Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation valued at up to $100 million. This acquisition expands Jupiter into a dual clinical-stage CNS company, adding …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter Neurosciences Enters License Agreement for Exclusive U.S. Rights to ALA-002, Expanding CNS Pipeline to Two Clinical-Stage Programs
Jupiter Neurosciences has secured exclusive U.S. rights to ALA-002, a patented MDMA formulation designated as a Novel Chemical Entity by the FDA, through a license agreement with PharmAla Biotech Holdings Inc. This deal, valued at up to $100 million, expands Jupiter's central nervous system …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla Biotech Holdings Inc. has announced a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive, perpetual U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla's lead drug candidate. The deal is valued at up to approximately US$100 million, including an upfront payment, milestone …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter enters psychedelics space with $100M deal for MDMA drug
Jupiter Neurosciences has acquired the U.S. rights to PharmAla Biotech's MDMA drug, ALA-002, for neuropsychiatric disorders, including PTSD. The deal includes an upfront payment of $3.3 million, with potential milestone payments and royalties totaling up to $100 million if the drug reaches Phase 3 …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This article identifies 12 healthcare stocks that are experiencing significant movement in pre-market trading on Tuesday. It lists both gainers, such as Jupiter Neurosciences and Imunon, and losers, including Zhengye Biotechnology and Lisata Therapeutics, along with their respective percentage changes and market capitalizations. The …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
Jupiter Neurosciences (NASDAQ:JUNS) has signed an exclusive U.S. licensing agreement with PharmAla Biotech Holdings for ALA-002, a clinical-stage psychedelic therapeutic candidate, valued at up to $100 million. This deal transforms Jupiter into a dual clinical-stage CNS company, expanding its pipeline beyond its Parkinson's disease …
JUNS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.4% · Next-week setup negative 35.1%